NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Short Interest Update

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) saw a large decline in short interest in the month of February. As of February 27th, there was short interest totaling 107,470 shares, a decline of 48.0% from the February 12th total of 206,623 shares. Currently, 0.2% of the shares of the company are short sold. Based on an average daily trading volume, of 214,706 shares, the days-to-cover ratio is presently 0.5 days. Based on an average daily trading volume, of 214,706 shares, the days-to-cover ratio is presently 0.5 days. Currently, 0.2% of the shares of the company are short sold.

Insider Buying and Selling

In other news, insider David J. Wambeke bought 1,000,000 shares of NeuroOne Medical Technologies stock in a transaction dated Sunday, March 1st. The stock was bought at an average price of $0.67 per share, for a total transaction of $670,000.00. Following the purchase, the insider owned 1,000,000 shares of the company’s stock, valued at approximately $670,000. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 8.90% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Sio Capital Management LLC purchased a new stake in shares of NeuroOne Medical Technologies in the 2nd quarter worth about $2,390,000. Vanguard Group Inc. increased its holdings in NeuroOne Medical Technologies by 31.2% during the 3rd quarter. Vanguard Group Inc. now owns 1,578,237 shares of the company’s stock valued at $1,403,000 after acquiring an additional 375,639 shares in the last quarter. Renaissance Technologies LLC raised its position in NeuroOne Medical Technologies by 10.2% during the fourth quarter. Renaissance Technologies LLC now owns 763,028 shares of the company’s stock worth $578,000 after acquiring an additional 70,428 shares during the last quarter. Essex Investment Management Co. LLC purchased a new stake in shares of NeuroOne Medical Technologies in the fourth quarter valued at about $143,000. Finally, Virtu Financial LLC purchased a new stake in shares of NeuroOne Medical Technologies in the third quarter valued at about $88,000. Hedge funds and other institutional investors own 16.07% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on NMTC. JonesTrading started coverage on shares of NeuroOne Medical Technologies in a report on Monday, March 2nd. They set a “buy” rating and a $1.50 price target for the company. Zacks Research raised NeuroOne Medical Technologies from a “hold” rating to a “strong-buy” rating in a report on Monday, January 5th. Finally, Wall Street Zen upgraded NeuroOne Medical Technologies to a “sell” rating in a research report on Saturday, February 21st. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $1.98.

NeuroOne Medical Technologies Price Performance

Shares of NASDAQ NMTC traded up $0.01 during trading on Thursday, hitting $0.80. 95,161 shares of the company were exchanged, compared to its average volume of 294,627. NeuroOne Medical Technologies has a 1 year low of $0.40 and a 1 year high of $1.16. The company has a market cap of $40.22 million, a price-to-earnings ratio of -4.68 and a beta of 0.74. The firm’s fifty day moving average price is $0.82 and its 200 day moving average price is $0.80.

NeuroOne Medical Technologies (NASDAQ:NMTC) last announced its quarterly earnings data on Tuesday, February 17th. The company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.04) by $0.01. The firm had revenue of $2.89 million during the quarter, compared to analysts’ expectations of $2.47 million. NeuroOne Medical Technologies had a negative net margin of 78.34% and a negative return on equity of 119.92%.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.